Cytyc’s Purchase Of Adiana Opens Door To Female Contraception Market
This article was originally published in The Gray Sheet
Executive Summary
Cytyc could gain PMA approval by year-end for its newly acquired, non-incisional alternative to tubal ligation for permanent female contraception, according to the company
You may also be interested in...
Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
Cytyc Gains Preterm Birth Diagnostic, Drug In $356 Mil. Adeza Acquisition
Cytyc is banking on its established women's health sales force to maximize the value of its $356 million purchase of Adeza Biomedical and its principal product Full Term, a diagnostic for preterm birth risk